Adalimumab biosimilar (CTTQ Pharma)

阿达木单抗生物类似药（正大天晴）

Report date: 2023/04/10 14:29:01

Base Information

Drug NameAdalimumab biosimilar (CTTQ Pharma)
Drug Alias Name阿达木单抗生物仿制药（正大天晴）Recombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (CTTQ Pharma)重组抗TNFa全人单抗 （正大天晴）重组抗肿瘤坏死因子-α全人源单抗（正大天晴）TQZ-2301 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[7] 
Global Approved IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Approved Indications in ChinaArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2022/01/18
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Inactive IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[5] 

Other Information

ATC CodeL04AB04
Related LinksN/A